Search
Non-Small Cell Lung Cancer Clinical Trials in Georgia
A listing of Non-Small Cell Lung Cancer clinical trials in Georgia actively recruiting patient volunteers.
1 - 12 of 22
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Non-Small Cell Lung Cancer
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
CMV Vaccine Trial For Young Women Ages 16-17
Recruiting
A Cytomegalovirus (CMV) Investigational Vaccine Clinical Trial for Healthy Women Age 16 to 17 years old. Compensation included.
Conditions:
Healthy Volunteers
Healthy
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Paid Vaccine Study For Teens
Recruiting
Vaccine study that aims to protect teens ages 12–17 against Epstein-Barr virus (EBV) and infectious mononucleosis (mono).
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Adult Migraine Study
Recruiting
Migraine study for adults. You may be compensated up to $800 for your time and travel expenses.
Conditions:
Headache
Cluster Headache
Headache Disorders
Post-Traumatic Headache
Migraine
Menstrual Migraine
Classic Migraine
Migraine
With or Without Aura
* Compensation for time may be available
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
Recruiting
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.
Gender:
All
Ages:
18 years and above
Locations: University Cancer & Blood Center, LLC; Research, Athens, Georgia +200 locations
Conditions: Non-Small Cell Lung Cancer
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
Recruiting
Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.
Gender:
All
Ages:
Between 18 years and 130 years
Locations: Research Site, Atlanta, Georgia +52 locations
Conditions: Non-Small Cell Lung Cancer
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Recruiting
This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans. There will be two parts and a sub-study.
The primary purpose of the parts are:
Dose Escalation: To investigate the safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended dose for expansion (RDE) of DS-1062a
Dose Expansion: To investigate the safety and tolerability of DS-... Read More
Gender:
All
Ages:
18 years and above
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia +17 locations
Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
Recruiting
This is a global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 non-small cell lung cancer following complete tumour resection.
Gender:
All
Ages:
18 years and above
Locations: Research Site, Atlanta, Georgia +178 locations
Conditions: Non-Small Cell Lung Cancer
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
Recruiting
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC).
Gender:
All
Ages:
18 years and above
Locations: Northside Hospital Central Research Department, Atlanta, Georgia +93 locations
Conditions: Non-small Cell Lung Cancer
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Recruiting
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Gender:
All
Ages:
18 years and above
Locations: Research Site, Macon, Georgia +226 locations
Conditions: Non-Small Cell Lung Cancer
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Recruiting
The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves overall response rate (ORR) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC).
Gender:
All
Ages:
18 years and above
Locations: Local Institution - 0089, Athens, Georgia +163 locations
Conditions: Recurrent Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Non-small Cell Lung Cancer
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer
Recruiting
This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC. Two populations will be included: participants with resected Stage II, IIIA, and selected IIIB (T3-N2) NSCLC who have completed adjuvant platinum-based chemotherapy without evidence of disease relapse/recurrence, and chemotherapy-naïve participants with Stage IV NSCLC. The study will evaluate participant- and healthcare professionals (HCP)-reported preference... Read More
Gender:
All
Ages:
18 years and above
Locations: Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia +50 locations
Conditions: Non-small Cell Lung Cancer
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Recruiting
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab or AZD0171 and platinum doublet chemotherapy; or MEDI5752 in combination with platinum doublet chemotherapy or datopotamab deruxtecan (Dato-DXd) in combination with durvalumab and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
Gender:
All
Ages:
Between 18 years and 95 years
Locations: Research Site, Gainesville, Georgia +94 locations
Conditions: Non-small Cell Lung Cancer
Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer
Recruiting
The development of stereotactic body radiation therapy (SBRT) for the treatment of stage I non-small cell lung cancer (NSCLC) has inspired a close partnership between thoracic surgery and radiation oncology. In this study, patients with stage I NSCLC will be screened prior to treatment and will be consented after their treatment plan has been determined. Prospectively collected patient-reported outcomes (PROs) will be collected for 3 years, as will outcomes data.
Gender:
All
Ages:
18 years and above
Locations: Emory University, Atlanta, Georgia +6 locations
Conditions: Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
Recruiting
This is a Phase 1a/1b study of aurora kinase A inhibitor VIC-1911 administered as monotherapy and in combination with sotorasib for the treatment of locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer(NSCLC).
Gender:
All
Ages:
18 years and above
Locations: Emory University Winship Cancer Center, Atlanta, Georgia +4 locations
Conditions: Non-small Cell Lung Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Recruiting
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
Gender:
All
Ages:
12 years and above
Locations: Emory University, Atlanta, Georgia +84 locations
Conditions: Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
1 - 12 of 22